Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CDC25A | P30304 | 6/20 | 0.32 |
| ▸ | CDC25B | P30305 | 6/20 | 0.32 |
| ▸ | CDC25C | P30307 | 5/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449761 | 0.98 | ACHE (0.38) | ACHEBACE1SCDDHFRALDH1A1 | |
| SCHEMBL20442366 | 0.71 | ALDH1A1 (0.35) | SCDALDH1A1GAAMAPTTHRB | |
| SCHEMBL12356587 | 0.67 | TSHR (0.40) | ACHEBACE1SCDALDH1A1THRB | |
| SCHEMBL4887906 | 0.67 | GAA (0.41) | ACHEBACE1SCDDHFRALDH1A1 | |
| SCHEMBL45540 | 0.67 | SORT1 (0.58) | ACHEBACE1SCDDHFRALDH1A1 | |
| SCHEMBL8798229 | 0.65 | SORT1 (0.56) | ACHEBACE1SCDDHFRALDH1A1 | |
| SCHEMBL7155537 | 0.63 | DHFR (0.38) | ACHEBACE1DHFRALDH1A1MAPT | |
| SCHEMBL13281066 | 0.63 | SCD (0.45) | ACHEBACE1SCDALDH1A1MAPT | |
| SCHEMBL4611630 | 0.63 | CDC25A (0.44) | ACHEBACE1SCDALDH1A1MAPT | |
| SCHEMBL13280457 | 0.63 | SCD (0.45) | ACHEBACE1SCDALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2435046-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMA CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2010137738-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | NR3C1, NR3C2, CRH | ACHE 2940/4885BACE1 2188/4885SCD 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.